Quality-of-life end points in cancer clinical trials: the U.S. Food and Drug Administration perspective.

Journal of the National Cancer Institute. Monographs

Volumn , Issue 20, 1996, Pages 7-9

  Beitz, J ^a   Gnecco, C ^a   Justice, R ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DRUG CONTROL; FOOD AND DRUG ADMINISTRATION; HUMAN; METHODOLOGY; NEOPLASM; PHASE 3 CLINICAL TRIAL; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; UNITED STATES;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE III; DRUG AND NARCOTIC CONTROL; HUMANS; NEOPLASMS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 0029686945     PISSN: 10526773     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (0)